ATAI
AtaiBeckley Inc.
$3.89
+2.10%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (95%)
Insider Activity0B / 2S
Insider Net $-$567.9K
Reddit Sentiment70° Bullish
SEC Reports3
Press Releases6
Recent Activity
Jun 9, 2026
short_volume
Short Volume: ATAI — 57.7% short (1.2M / 2.1M)
Short: 1,186,002 | Exempt: 2,093 | TRF Vol: 2,057,069 | Short Ratio: 57.7% | Off-exchange volume (da
Jun 4, 2026
Insider
Fischer Laurent sold 121,968 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
JOHNSON SABRINA MARTUCCI sold 121,968 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Kalali Amir H sold 121,968 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
SEC
AtaiBeckley filed an 8-K announcing management's participation in four investor conferences in June 2026, including the
8-K — Impact 2/10
May 12, 2026
SEC
AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K, well above the $91
PRESS-RELEASE — Impact 5/10
Apr 27, 2026
Press
AtaiBeckley Inc. received the Silver Award in OVID Health’s 2026 Patient Participant Index for its collaboration with th
Impact 3/10
Apr 20, 2026
SEC
Craig Kevin James, an officer of AtaiBeckley Inc., filed a Form 144 to notify the SEC of his intent to sell up to 42,579
144 — Impact 3/10
Price Targets
$14.00
+259.9% upside
Strong Buy
Current $3.89
Low $7.00
Median $14.50
High $25.00
12 analysts
$7.00
$25.00
Analyst Ratings
5Strong Buy
14Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Apr 17, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Mar 27, 2026 | Deutsche Bank | INITIATE | Buy |
| Mar 17, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▲ +8.2% | $-0.21 — $-0.08 | 18% YoY | 8 |
| Next Q | $-0.12 ▲ +8.7% | $-0.21 — $-0.08 | 56% YoY | 8 |
| Current FY | $-0.44 ▲ +9.3% | $-0.74 — $-0.33 | 85% YoY | 9 |
| Next FY | $-0.46 ▲ +6.3% | $-0.60 — $-0.40 | -3% YoY | 7 |
Latest Reports
NEUTRAL
8-K
2/10
AtaiBeckley filed an 8-K announcing management's participation in four investor conferences in June 2026, including the
Jun 3, 2026
MIXED
PRESS-RELEASE
5/10
AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K, well above the $91
May 12, 2026
NEUTRAL
Press
3/10
AtaiBeckley Inc. received the Silver Award in OVID Health’s 2026 Patient Participant Index for its collaboration with th
Apr 27, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Fischer Laurent | A | $0.00 |
| Jun 4, 2026 | JOHNSON SABRINA | A | $0.00 |
| Jun 4, 2026 | Kalali Amir | A | $0.00 |
| Jun 4, 2026 | Smiley Andrea | A | $0.00 |
| Jun 4, 2026 | HERSHBERG ROBERT | A | $0.00 |
Reddit Sentiment
70°▲
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
15 unique insiders with 2 transactions. Net insider value: -$567.9K ($0.00 bought, $567.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Fischer Laurent | Director | A | 121,968 | $0.00 | $0.00 |
| Jun 4, 2026 | JOHNSON SABRINA MARTUCCI | Director | A | 121,968 | $0.00 | $0.00 |
| Jun 4, 2026 | Kalali Amir H | Director | A | 121,968 | $0.00 | $0.00 |
| Jun 4, 2026 | Smiley Andrea Heslin | Director | A | 121,968 | $0.00 | $0.00 |
| Jun 4, 2026 | HERSHBERG ROBERT | Director | A | 121,968 | $0.00 | $0.00 |
| Jun 4, 2026 | Braunstein Scott | Director | A | 121,968 | $0.00 | $0.00 |
| Jun 4, 2026 | Hoffman John Francis | Director | A | 121,968 | $0.00 | $0.00 |
| Jun 4, 2026 | Angermayer Christian | Director | A | 121,968 | $0.00 | $0.00 |
| Apr 20, 2026 | Craig Kevin James | Chief Medical Officer | M | 27,280 | $1.50 | $40.9K |
| Apr 20, 2026 | Craig Kevin James | Chief Medical Officer | SELL | 42,579 | $5.00 | $212.9K |
| Apr 20, 2026 | Craig Kevin James | Chief Medical Officer | M | 27,280 | $0.00 | $0.00 |
| Apr 8, 2026 | Angermayer Christian | Director | M | 46,070 | $1.88 | $86.6K |
| Apr 8, 2026 | Angermayer Christian | Director | M | 46,070 | $0.00 | $0.00 |
| Mar 20, 2026 | Craig Kevin James | Chief Medical Officer | M | 76,224 | $0.00 | $0.00 |
| Mar 20, 2026 | Craig Kevin James | Chief Medical Officer | M | 76,224 | $1.18 | $89.9K |
| Mar 20, 2026 | Craig Kevin James | Chief Medical Officer | SELL | 100,000 | $3.55 | $355.0K |
| Mar 11, 2026 | Faerm Michael E. | Chief Financial Officer | A | 285,000 | $0.00 | $0.00 |
| Mar 11, 2026 | Faerm Michael E. | Chief Financial Officer | A | 1,275,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Kochendoerfer Gerd | Chief Operating Officer | A | 675,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Kochendoerfer Gerd | Chief Operating Officer | A | 150,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Rao Srinivas | See remarks | A | 1,988,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Rao Srinivas | See remarks | A | 442,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Barrett Christopher Ryan Cave | See remarks | A | 675,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Barrett Christopher Ryan Cave | See remarks | A | 150,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Johnson Anne Nagengast | Chief Financial Officer | A | 525,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Johnson Anne Nagengast | Chief Financial Officer | A | 117,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Short Glenn Frank | Chief Scientific Officer | A | 675,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Short Glenn Frank | Chief Scientific Officer | A | 150,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Craig Kevin James | Chief Medical Officer | A | 675,000 | $0.00 | $0.00 |
| Jan 30, 2026 | Craig Kevin James | Chief Medical Officer | A | 150,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.3/10.
NEUTRAL
8-K
2/10
AtaiBeckley filed an 8-K announcing management's participation in four investor conferences in June
Jun 3, 2026
MIXED
PRESS-RELEASE
5/10
AtaiBeckley reported Q1 2026 EPS of -$0.08, beating consensus of -$0.11 by 27%, and revenue of $954K
May 12, 2026
NEUTRAL
144
3/10
Craig Kevin James, an officer of AtaiBeckley Inc., filed a Form 144 to notify the SEC of his intent
Apr 20, 2026
NEUTRAL
3/10
AtaiBeckley Inc. received the Silver Award in OVID Health’s 2026 Patient Participant Index for its c
Apr 27, 2026
BULLISH
8/10
AtaiBeckley announced positive Phase 2a results for BPL-003 in treatment-resistant depression, showi
Apr 8, 2026
NEUTRAL
5/10
AtaiBeckley Inc. (ATAI) was added to the S&P Total Market Index, S&P Completion Index, and CRSP U.S.
Mar 24, 2026
BULLISH
8/10
AtaiBeckley Inc. announced the peer-reviewed publication of positive Phase 2a data for its intranasa
Mar 17, 2026
BULLISH
8/10
AtaiBeckley Inc. announced progress in advancing its lead candidate BPL-003 into Phase 3 trials for
Mar 10, 2026
MIXED
6/10
AtaiBeckley Inc. reported its Q4 and full-year 2025 financial results, highlighted by a successful F
Mar 6, 2026
Current analyst consensus: Strong Buy (95% buy). Based on 20 analysts: 5 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.00 mean target
+259.9% upside
Strong Buy (1.14)
$7.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $3.89 |
| Target Low | $7.00 |
| Target Mean | $14.00 |
| Target Median | $14.50 |
| Target High | $25.00 |
| # Analysts | 12 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.21 | $-0.08 | 18.3% | +8.2% | 3↑ 2↓ | $0.0B | -88.4% | 8 |
| Next Q 2026-09-30 |
$-0.12 | $-0.21 | $-0.08 | 56.3% | +8.7% | 2↑ 2↓ | $0.0B | -88.9% | 8 |
| Current FY 2026-12-31 |
$-0.44 | $-0.74 | $-0.33 | 84.9% | +9.3% | 3↑ 3↓ | $0.0B | -72.9% | 9 |
| Next FY 2027-12-31 |
$-0.46 | $-0.60 | $-0.40 | -3.4% | +6.3% | 1↑ 4↓ | $0.0B | -73.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.114 | |
| 7d ago | $-0.112 | -0.003 |
| 30d ago | $-0.125 | +0.010 |
| 60d ago | $-0.125 | +0.010 |
| 90d ago | $-0.125 | +0.011 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 27, 2026 | Deutsche Bank | INITIATE | — | Buy |
| Mar 17, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 9, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Guggenheim | INITIATE | — | Buy |
| Dec 23, 2025 | Jones Trading | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 5 | 14 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 5 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 5 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 4 | 13 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
70°
Bullish
Bearish
Neutral
Bullish
18 mentions
11 bullish
2 bearish
15 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 2, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Feb 27, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Feb 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 18, 2026 | 3 | 57° Neutral | 1 | 0 | 3 |
| Feb 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 9, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
5 Penny Stocks That Might Be About to Take Off
▲ 1
💬 1
⚡ 0.5
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
▲ 1
💬 1
⚡ 0.5
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
▲ 1
💬 0
⚡ 0.5
Here’s what $ATAI is actually building🧬
▲ 1
💬 1
⚡ 0.5
$ATAI isn’t just biotech noise
▲ 1
💬 1
⚡ 0.5
Recent update on $ATAI
▲ 1
💬 1
⚡ 0.0
Update on $ATAI
▲ 1
💬 1
⚡ 0.0
Recent update from $ATAI
▲ 1
💬 0
⚡ 0.0
Recent update on $ATAI
▲ 1
💬 0
⚡ 0.0
Recent update on $ATAI
▲ 1
💬 0
⚡ 0.0
$ATAI and the new approach to curing depression
▲ 13
💬 2
⚡ 0.0
AtaiBeckley $ATAI Provides Update and Outlook for 2026
▲ 5
💬 4
⚡ 0.0
Jun 9, 2026
short_volume
Short Volume: ATAI — 57.7% short (1.2M / 2.1M)
Short: 1,186,002 | Exempt: 2,093 | TRF Vol: 2,057,069 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: ATAI — 58.8% short (1.6M / 2.7M)
Short: 1,562,517 | Exempt: 2,478 | TRF Vol: 2,658,265 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: ATAI — 57.6% short (1.1M / 1.8M)
Short: 1,054,805 | Exempt: 56,486 | TRF Vol: 1,832,183 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: ATAI — 55.9% short (1.2M / 2.1M)
Short: 1,186,537 | Exempt: 4,800 | TRF Vol: 2,120,974 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
<p>NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company o
May 19, 2026
short_volume
Short Volume: ATAI — 64.3% short (1.3M / 2.1M)
Short: 1,332,306 | Exempt: 2,938 | TRF Vol: 2,070,599 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: ATAI — 56.0% short (0.8M / 1.5M)
Short: 818,155 | Exempt: 1,805 | TRF Vol: 1,460,018 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
<p align="justify">NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotech
May 12, 2026
short_volume
Short Volume: ATAI — 56.6% short (1.4M / 2.4M)
Short: 1,375,232 | Exempt: 46,771 | TRF Vol: 2,431,137 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
ATAI Q1 2026 Earnings Scheduled — 2026-05-11
May 5, 2026
short_volume
Short Volume: ATAI — 59.9% short (1.2M / 2.0M)
Short: 1,195,846 | Exempt: 3,189 | TRF Vol: 1,996,550 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: ATAI — 65.9% short (2.2M / 3.4M)
Short: 2,221,830 | Exempt: 2,209 | TRF Vol: 3,369,159 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
May 1, 2026
Clinical Trial
Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
Phase Phase 2 — COMPLETED
May 1, 2026
clinical_trial_readout
Results Pending: EMP-01 (Phase 2) — Completed 78d ago
Trial: Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder
Sponsor: atai Therapeutics, Inc.
Phase: Phase 2 | Completed: 2026-02-12
Co
May 1, 2026
short_volume
Short Volume: ATAI — 60.6% short (0.7M / 1.1M)
Short: 682,716 | Exempt: 16,396 | TRF Vol: 1,126,017 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
contract
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
<p>NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company